Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Recommendation is based on pivotal data from the phase III POLARIX study
The expansion makes Exothera one of the largest viral vector facilities in Europe
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Data published in the prestigious journal ACS Central Science of the American Chemical Society
All of Us Research Program releases genomic data to researchers, combined with participant-generated data collected on Vibrent Health’s research platform
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Subscribe To Our Newsletter & Stay Updated
